Microsatellite Instability Serves as a Predictive Biomarker of Response to Pembrolizumab
Joseph Chao, MD, discusses the importance of assessing the microsatellite instability (MSI) status in patients with advanced gastric/gastroesophageal junction cancer based on findings from a comparative analysis of KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062.
Joseph Chao, MD, assistant professor of Medical Oncology Research at the City of Hope, discusses the importance of assessing the microsatellite instability (MSI) status in patients with advanced gastric/gastroesophageal junction (GEJ) cancer based on findings from a comparative analysis of KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062.
The prognosis for patients with stage IV gastric/GEJ cancer is fairly poor, Chao says. With the current treatment landscape, however, patients with MSI-high disease who receive treatment with a PD-1 inhibitor, such as pembrolizumab (Keytruda), have a vastly improved prognosis.
Based on the data from this analysis, which Chao presented at the 2020 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, MSI-high patients who do not receive PD-1 inhibition therapy have a fairly poor prognosis. Therefore, it is important to look for MSI status as a predictive biomarker for treatment with pembrolizumab.
<< View more from the 2020 Gastrointestinal Cancers Symposium
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More
